The development of PARP inhibitors in ovarian cancer: from bench to bedside
Crossref DOI link: https://doi.org/10.1038/bjc.2015.394
Published Online: 2015-12-15
Published Print: 2015-12-15
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Drew, Yvette
Text and Data Mining valid from 2015-12-15
Version of Record valid from 2015-12-15
Article History
First Online: 15 December 2015
Competing interests
: Dr Yvette Drew has previously received honoraria as a clinical advisory board member for AstraZeneca and for Clovis Oncology.